Table 1 Baseline clinical and biochemical characteristics of 7074 Chinese Type 2 diabetic patients without clinical evidence of coronary heart disease and heart failure at enrollment during 5.52 years of follow-up in the training dataset and the test dataset
| Â | Training dataset (n = 3456) | Test dataset (n = 3611) | ||
|---|---|---|---|---|
| Â | median or % | IQR* | median or % | IQR* |
Male Gender | 45.2% | Â | 45.6% | Â |
Smoking status | Â | Â | Â | Â |
   Current smoker | 20.4% |  | 20.7% |  |
   Ex smoker | 13.1% |  | 13.8% |  |
Age (year) | 57 | 21 | 57 | 21 |
Body mass index (kg/m2) | 24.6 | 4.8 | 24.7 | 5.0 |
Years of diagnosed diabetes | 5 | 10 | 5 | 9 |
Systolic BP (mmHg) | 134 | 27 | 134 | 28 |
Diastolic BP (mmHg) | 76 | 13 | 76 | 15 |
HbA1c (%) | 7.3 | 2.2 | 7.4 | 2.2 |
Blood haemoglobin (g/L) | 13.8 | 2.1 | 13.8 | 2.2 |
White blood cell count (109/counts/L) | 7.0 | 2.4 | 7.0 | 2.4 |
Spot urinary albumin creatinine ratio (mg/mmol) | 2.0 | 10.1 | 2.0 | 10.0 |
eGFR (ml min-1 1.73 m-2) ξ | 104.9 | 43.0 | 104.9 | 43.5 |
LDL-C (mmol/l) | 3.13 | 1.24 | 3.11 | 1.29 |
HDL-C (mmol/l) | 1.24 | 0.45 | 1.25 | 0.45 |
Triglyceride (mmol/L) | 1.37 | 1.08 | 1.39 | 1.12 |
Non-HDL cholesterol (mmol/L) | 3.87 | 1.40 | 3.87 | 1.43 |
Drug use at baseline | Â | Â | Â | Â |
On diet treatment | 10.2% | Â | 9.9% | Â |
Use of oral anti-diabetic drugs | 61.0% | Â | 60.6% | Â |
Use of anti-hypertensive drugs | 34.1% | Â | 33.3% | Â |
Use of insulin | 17.5% | Â | 17.4% | Â |
Use of LLD§ | 11.6% |  | 13.2% |  |
Use of ACEI or ARB¶ | 20.4% |  | 20.1% |  |
Complications at baseline | Â | Â | Â | Â |
Retinopathy | 25.4% | Â | 27.4% | Â |
Sensory neuropathy | 26.0% | Â | 25.7% | Â |
Peripheral arterial disease | 5.8% | Â | 5.9% | Â |
History of stroke | 3.6% | Â | 4.4% | Â |
Complications during follow-up | Â | Â | Â | Â |
Coronary heart disease before heart failure during follow-up | 4.4% | Â | 4.4% | Â |
Heart failure hospitalisation during follow-up | 3.8% | Â | 4.0% | Â |
Death during follow-up | 9.4% | Â | 9.9% | Â |